Has Keith Schmidt, MD received payments from drug or device companies?

Yes. Drug and device makers reported $80,836 in general payments to Keith Schmidt, MD across 463 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Keith Schmidt, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Keith Schmidt, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Keith Schmidt, MD

Pain Medicine · Hoffman Estates, ILNPI 1407162746

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $54,112 of the $80,836 with a category attached, or 66.9%. 22 manufacturers reported payments, led by Abbott at 49.6% of the total. Reporting peaked in 2019 at $27,887 and has fallen 99.0% since, to $283 in 2025. Among pain medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$80,836in general payments, 2019–2025

Across 463 payments — averaging $174.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$40K
Nevro Corp.$28K
Boston Scientific$8K
Vertiflex, Inc.$3K
Saluda Medical Americas, Inc.$256
SPR Therapeutics, Inc$144
plus $706 from 16 others

What the payments were for

Consulting fees$54,11267%
Speaking & faculty fees$8,85711%
Travel & lodging$8,49411%
Food & beverage$9,37312%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	265	$40,076
Nevro Corp.	117	$28,314
Boston Scientific	23	$8,317
Vertiflex, Inc.	20	$3,021
Saluda Medical Americas, Inc.	3	$256
SPR Therapeutics, Inc	7	$144
Stryker	1	$139
Medtronic	1	$72
Vertos Medical, Inc.	4	$70
Melinta Therapeutics, LLC	4	$67
Fresenius Kabi USA, LLC	2	$58
Daiichi Sankyo Inc.	2	$53
Takeda Pharmaceuticals U.S.A., Inc.	2	$46
Amgen	2	$37
Painteq LLC	2	$30
AstraZeneca	1	$27
OWP Pharmaceuticals, Inc.	2	$25
Aquestive Therapeutics, Inc.	1	$20
UCB, Inc.	1	$19
Coherus Oncology, Inc.	1	$17
Stimwave Technologies Incorporated	1	$13
Flowonix Medical Incorporated	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Neuromodulation Dspsbls and Accs$31,312
Senza Spinal Cord Stimulation System$13,618
Omnia$12,170
GENERAL PAIN MANAGEMENT$8,046
Superion ISS$2,650
IonicRF Generator$2,556
Proclaim Family of SCS IPGs$1,159
Proclaim XR IPG$978
Proclaim DRG IPG$378
Senza$284
Nevro$222
PROCLAIM$149
Evoke SCS$143
SPINEJACK$139
Proclaim IPG$125
ETERNA$116

How this compares

$80,836 in reported general payments places this provider in the 95th percentile of 233 pain medicine providers in Illinois.

See all pain medicine providers in Illinois →

Medicare billing

Part B allowed, 2024

$151,001

Medicare patients

398

Services billed

1,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OxycontinOxycodone Hcl	22	$25,017
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	455	$15,976
MovantikNaloxegol Oxalate	20	$10,974
Fentanyl	57	$9,646
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	105	$5,500
Gabapentin	282	$3,771
Morphine Sulfate ErMorphine Sulfate	62	$3,753
Lidocaine	32	$3,631
Tizanidine Hcl	297	$3,543
Oxycodone Hcl	118	$3,358
Baclofen	71	$1,727
Cyclobenzaprine Hcl	109	$1,570
Morphine Sulfate	25	$1,111
Tramadol Hcl	147	$964
Pregabalin	50	$852

Paid to pharmacies, not to this prescriber.

Other pain medicine in Hoffman Estates

Wajde DabahHoffman Estates$37K
Ricardo VallejoBloomington$2.3M
David DickersonEvanston$558K
Thomas DahlbergRockford$218K
Steven CohenChicago$217K
Albert SinghQuincy$212K
Nirav ShahSkokie$137K
Ryan KutaNaperville$114K
Anthony LebarioElgin$87K
Jay HurhLibertyville$71K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →